DALLAS, November 28, 2014 /PRNewswire/ --
ReportsnReports.com adds PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 research report that says asthma treatment market value will grow across eight major countries (the US, UK, France, Germany, Spain, Italy, Japan, and Australia) to $23.1 billion by 2023. Complete report of 383 pages is available at http://www.reportsnreports.com/reports/319051-pharmapoint-asthma-global-drug-forecast-and-market-analysis-to-2023.html.
The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers. The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol) and Symbicort (budesonide/formoterol fumarate). Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.
While the market share of fixed-dose combinations of inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs) will shrink from almost half to 23%, targeted biologics will enter the market and start dominating the asthma space, accounting for 32% of total sales in 2023 from just 8.7% in 2013.The uptake of these novel drugs will offset the dip in sales caused by the recent patent expiry of Singulair, and that of numerous short-acting beta-agonist, ICS, and ICS/LABA products. While the subpopulations targeted by pipeline biologics are limited in size, these novel agents will begin to fulfill the important unmet need for a personalized approach to the treatment of severe asthma. Despite the development of these biologics, a significant growth opportunity will persist for new patented products, especially lower-priced drugs with more convenient dosing, which will improve patient compliance.
The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. This research states that the companies with the strongest drug pipelines are GlaxoSmithKline, AstraZeneca, Teva, Roche and Regeneron/Sanofi. Companies profiled in this report include GlaxoSmithKline, Merck & Co., AstraZeneca/MedImmune, Novartis, Roche/Genentech, Teva and Boehringer Ingelheim. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=319051 .
The PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 research report helps answer questions like what are the main unmet needs in this market. Will the drugs under development fulfil the unmet needs of the asthma market? Will the late-stage drugs make a significant impact on the asthma market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market? The prevalence of environmental diseases, including asthma, is increasing worldwide, with an estimated 400 million people likely to suffer from asthma in 2025. How will epidemiological changes impact the growth of the future market? The report provides an overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs. Analysis of the current and future market competition in the global asthma therapeutics market and Insightful review of the key industry drivers, restraints and challenges are covered in this research. Each trend is independently researched to provide qualitative analysis of its implications.
Request a Sample to evaluate the content format and structure or order a copy of this asthma drug market report that can help the reader: Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list; Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market; Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future; Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors; Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage; Track drug sales in the global asthma therapeutics market from 2013-2023 and organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
On the same lines, EpiCast Report: Asthma - Epidemiology Forecast to 2023 is a 87 pages market research that says in 2013, there were 137.66 million lifetime prevalent cases of asthma in the 10MM, with 82.71 million cases in the US (43.16 million cases) and India (39.55 million cases) combined. This research forecasts that there will be approximately 161.02 million lifetime prevalent cases of asthma in the 10MM by 2023, with an overall growth of 17.0% over the next decade. This Asthma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for asthma in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India). It includes a 10-year epidemiological forecast of the lifetime prevalent cases of asthma segmented by sex, age (in five-year increments beginning at 0 years and ending at =85 years), and asthma severity in these markets. The Asthma epidemiology report is written and developed by Mastersand PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM. Comprehensive table of contents and more on this research is available at http://www.reportsnreports.com/reports/297968-epicast-report-asthma-epidemiology-forecast-to-2023.html .
Explore more reports on asthma market as well as other newly published research on pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ and overall healthcare sector at http://www.reportsnreports.com/market-research/healthcare/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts